Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments

Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia, hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic malignancies. Although the therapeutic landscape of MM has evolved spectacularly over the past decades with 5-year median survival ove...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer letters Jg. 414; S. 214 - 221
Hauptverfasser: Hu, Jingping, Hu, Wei-Xin
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Ireland Elsevier B.V 01.02.2018
Elsevier Limited
Schlagworte:
Apoptosis
Blood cancer
Bone diseases
Bone lesions
Bone marrow
Cancer
Cell cycle
Cell growth
Cytokines
Cytotoxicity
Insulin-like growth factors
Kinases
Ligands
Multiple myeloma
Pathogenesis
Phosphorylation
Signal transduction
Signaling pathway
Stem cell transplantation
Targeting therapy
Signaling pathway
Multiple myeloma
Targeting therapy
ISSN:0304-3835, 1872-7980, 1872-7980
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia, hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic malignancies. Although the therapeutic landscape of MM has evolved spectacularly over the past decades with 5-year median survival over 50%, most of these patients relapse eventually. The widely recognized therapeutic approaches include chemotherapy, radiation, stem cell transplant, and monoclonal antibody therapy. Former studies have implied that the proliferation, survival, migration and drug resistance of MM cells are in association with the activation of several signaling pathways. In this review, we intended to focus on the major signaling pathways such as PI3K/Akt/mTOR, Ras/Raf/MEK/MAPK, JAK/STAT, NF-κB, Wnt/β-catenin, and RANK/RANKL/OPG, that contribute to the pathogenesis of the MM and the therapeutic approaches developed to target them. •Summarized the most important signaling pathways that participated in the pathogenesis of multiple myeloma.•Summarized the evaluation methods and therapeutic strategies developed for these signaling pathways.•Implications for future directions with these signaling pathways.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0304-3835
1872-7980
1872-7980
DOI:10.1016/j.canlet.2017.11.020